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The impact of whole human blood on the kinetic
inertness of platinum(IV) prodrugs – an
HPLC-ICP-MS study†
Sarah Theiner, a Márkó Grabarics, b Luis Galvez,a Hristo P. Varbanov, c
Nadine S. Sommerfeld,c Markus Galanski,c Bernhard K. Kepplerc,d and
Gunda Koellensperger*a
The potential advantage of platinum(IV) complexes as alternatives to classical platinum(II)-based drugs
relies on their kinetic stability in the body before reaching the tumor site and on their activation by
reduction inside cancer cells. In this study, an analytical workflow has been developed to investigate the
reductive biotransformation and kinetic inertness of platinum(IV) prodrugs comprising different ligand
coordination spheres (respectively, lipophilicity and redox behavior) in whole human blood. The distri-
bution of platinum(IV) complexes in blood pellets and plasma was determined by inductively coupled
plasma-mass spectrometry (ICP-MS) after microwave digestion. An analytical approach based on
reversed-phase (RP)-ICP-MS was used to monitor the parent compound and the formation of metab-
olites using two different extraction procedures. The ligand coordination sphere of the platinum(IV) com-
plexes had a significant impact on their accumulation in red blood cells and on their degree of kinetic
inertness in whole human blood. The most lipophilic platinum(IV) compound featuring equatorial chlorido
ligands showed a pronounced penetration into blood cells and a rapid reductive biotransformation. In
contrast, the more hydrophilic platinum(IV) complexes with a carboplatin- and oxaliplatin-core exerted
kinetic inertness on a pharmacologically relevant time scale with notable amounts of the compound
accumulated in the plasma fraction.
Introduction
Platinum(IV) complexes have the potential to overcome the
shortcomings of established platinum(II)-based drugs (severe
side effects, intravenous administration and acquired tumor
resistance), due to their higher kinetic inertness to ligand-
exchange reactions. Based on the prodrug-concept, platinum(IV)
compounds are considered to reach the tumor site mainly
in their intact form and to be activated to their platinum(II)
analogues by reduction advantageously only inside cancer
cells, resulting in less side effects and a lower toxicity profile
and making them amenable for oral administration.1–3
However, most of our knowledge on the reduction of platinum(IV)
prodrugs is based on experiments using simple model
systems mimicking physiological conditions (e.g. ascorbate,
cysteine, glutathione or other biological reducing agents in
PBS)4,5 Initial studies were focused on platinum(IV) complexes,
featuring a cisplatin-like core and indicated that the rate of
reduction strongly depends on the nature of the axial ligands.
Complexes with axial hydroxido ligands are the most resistant
ones, agents bearing axial carboxylato ligands exhibit inter-
mediate reduction rates, while those carrying axial chlorido
ligands are the most readily and rapidly reduced platinum(IV)
compounds.6 More recently, also the significant role of equa-
torial ligands in the reduction rate of platinum(IV) prodrugs
has been shown: complexes with equatorial chlorido ligands
are reduced more rapidly than their counterparts with carboxy-
lato ligands.7–9 Despite these structure–activity relationships
established in model systems (usually consisting of one redu-
cing agent), little is known about the behavior of platinum(IV)
compounds in complex biological fluids (e.g. in serum or
blood) or in vivo. The incubation of platinum(IV) compounds
in aqueous extracts from different cancer cell lines demon-
strated that high molecular weight biomolecules account for
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the majority of the reduction in cells and that the rate of
reduction is dependent on the cell line used.10,11 In the litera-
ture, some data are available regarding the in vivo metabolism
of individual platinum(IV) complexes that have undergone
clinical trials (iproplatin, tetraplatin and satraplatin).12 In the
case of satraplatin, seven platinum-containing species were
already found in patient’s plasma ultrafiltrate 15 min after oral
administration whereas the parent compound could not be
detected any more.13 Rapid biotransformation of satraplatin
was also observed upon incubation with human red blood
cells14 and with hemoglobin and cytochrome c in the presence
of NADH.15 Hambley et al. investigated the reactivity of plati-
num(IV) complexes with different ligand coordination spheres
towards selected plasma constituents (including human serum
albumin and cysteine) and correlated the results with the
reduction potentials.16
A variety of analytical techniques have been used to study
platinum compounds and their interactions with proteins in
blood compartments, including nuclear magnetic resonance
(NMR) spectroscopy, electrospray ionization-mass spec-
trometry (ESI-MS) and atomic absorption spectroscopy
(AAS).4,5 In recent years, hyphenated techniques combining
chromatographic separation with sensitive and element-
specific detection techniques such as inductively coupled
plasma-mass spectrometry (ICP-MS) have been effectively used
to study the behavior of metallodrugs in biological systems.17
These studies addressed different aspects including e.g. the
interaction of metallodrugs with serum proteins,18–21 protein
binding kinetics, the reversibility of protein binding and the
investigation of hydrolysis products and metabolites of metal-
lodrugs22 on a qualitative and/or quantitative basis.23–25
In this study, we present an analytical workflow based on
extraction procedures and a RP-ICP-MS method to investigate
the biotransformation of platinum(IV) complexes in whole
human blood. For this purpose, three hydrophilic complexes
featuring a carboplatin- or oxaliplatin-core and two hydroxides
or acetates on axial positions, together with one more lipophi-
lic cisplatin analogue comprising two axial ethoxysuccinato
ligands, were chosen for the study (Fig. 1). The impact of the
coordination sphere on the penetration of the compounds into
the blood cells and on their kinetic stability in whole blood
was also evaluated.
Experimental
Chemicals and reagents
Ultrapure water (resistivity ≥ 18.2 MΩ cm) was obtained from a
Milli-Q Element water purification system (Milli-Q Advantage,
Darmstadt, Germany) and used for RP-ICP-MS experiments
and for all dilutions for ICP-MS measurements. Nitric acid
(≥69%, p.a., TraceSelect, Fluka) was used for ICP-MS measure-
ments. Elemental standard stock solutions of platinum and
rhenium were obtained from CPI International (Amsterdam,
The Netherlands). All other reagents and solvents were
obtained from commercial sources and were used without
further purification.
Complex 1 ((OC-6-33)-dihydroxido(1R,2R-diaminocyclo-
hexane)oxalatoplatinum(IV)), complex 2 ((OC-6-33)-diacetato
(1R,2R-diaminocyclohexane)oxalatoplatinum(IV)) and complex
3 ((OC-6-33)-diacetatodiammine(1,1-cyclobutanedicarboxylato)-
platinum(IV)) were synthesized according to literature pro-
cedures.26,27 The synthesis and characterization of complex 4
((OC-6-33)-dichloridobis((4-ethoxy)-4-oxobutanoato)bis(ethylamine)
platinum(IV)) are described in ref. 9 and 28. The chemical for-
mulae of the platinum(IV) complexes used in this study are shown
in Fig. 1.
Determination of the platinum concentration in blood
compartments by ICP-MS
Fresh human whole blood samples (collected in heparinized
tubes), drawn in the framework of a biomarker study approved
by the ethics committee of the Medical University of Vienna,
were spiked ex vivo with an aqueous solution of the platinum(IV)
complexes (1 mM) to reach a final concentration of ∼10 µM.
The platinum concentrations were normalized to the hemato-
crit value of the whole blood (HCT = 47%) and the density of
plasma and blood pellets. Incubation was performed at 37 °C
for different time periods (0 h, 0.5 h, 1 h, 2 h and 24 h). The
separation of the blood plasma and blood cells was performed
by centrifugation for 10 min at 2000 rcf, using a Hermle Z
446 K device (Hermle Labortechnik, Wehingen, Germany) with
a pre-cooled rotor (4 °C). Clear fractions of the supernatant
(plasma) and the pellet (blood cells) were stored at −20 °C
until further processing. Microwave-assisted acid digestion was
performed by adding 2 mL of 25% nitric acid to a 50 µL
aliquot of each sample using a Discover SP-D (CEM Microwave
Technology, Germany) microwave device operating with the
following parameters: temperature – 200 °C, ramp time –
Fig. 1 Chemical formulae of the platinum(IV) compounds under
investigation.
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4 min, hold time – 6 min, and maximal power – 300
W. The digested samples were further diluted with ultrapure
water to achieve platinum levels in the working range of 0.1 to
20 µg L−1. The determination of total platinum concentrations
was performed by ICP-MS measurements, using an Agilent
7500ce quadrupole-based ICP-MS instrument (Agilent
Technologies, Waldbronn, Germany). The ICP-MS parameters
were tuned on a daily basis to achieve maximum sensitivity.
The ICP-MS was equipped with a CETAC ASX-520 autosampler
(Nebraska, USA), a MicroMist nebulizer with a sample uptake
rate of ∼0.25 mL min−1, and standard nickel cones. Data pro-
cessing was performed with the Agilent MassHunter software
package (Workstation Software 4.3, Version B.01.01, 2012). The
instrumental parameters of the ICP-MS measurements are
summarized in Table S1.†
Extraction of platinum(IV) compounds from whole blood using
cold organic extraction (Method A)
The spiking of fresh human blood (collected in heparinized
tubes) was performed by adding 10 µL of 100 µM aqueous
solution of platinum(IV) compounds to 90 µL of fresh whole
human blood. 900 µL ice-cold acetonitrile was added to the
spiked blood samples to disrupt cells and precipitate proteins,
followed by 15 s of vortexing. The samples were shaken for
30 s, sonicated for 1 min and again vortexed for 15 s. Finally,
the samples were centrifuged for 1 min at 14 000 rpm using a
Hettich Mikro 120 device (Hettich Zentrifugen, Tuttlingen,
Germany). The supernatants were filtered directly into HPLC
vials, using Sartorius Minisart syringe filters with a pore size
of 0.45 µm and diluted in the ratio of 1 : 5 with 50 mM
ammonium-formate buffer (pH = 6.0). The vials were placed
into the pre-cooled autosampler (4 °C) of the HPLC system for
RP-ICP-MS analysis. In order to determine the extraction recov-
ery, the weight of the filtered supernatants was measured and
a 500 µL aliquot of each filtrate was weighed, followed by the
addition of 2 mL 25% nitric acid. The samples were digested
using a Discover SP-D (CEM Microwave Technology, Germany)
microwave device with the following parameters: temperature –
200 °C, ramp time – 4 min, hold time – 6 min, and maximal
power – 300 W. The platinum concentration of the samples
was measured by ICP-MS, using the same conditions as
described above with the instrumental parameters summar-
ized in Table S1.†
Extraction of platinum(IV) compounds from whole blood with
acidic extraction and freeze-thawing (Method B)
The spiking was performed by adding 20 µL of 100 µM
aqueous drug solution to 180 µL fresh whole human blood
and 200 µL of 0.1% HCOOH was added to the spiked blood
samples, followed by vortexing for 15 s. The samples were
transferred onto dry-ice for 1 min (freezing) and then soni-
cated for 1 min using a water bath of 20 °C (thawing). The
samples were vortexed for 15 s and centrifuged for 1 min at
14 000 rpm using a Hettich Mikro 120 device (Hettich
Zentrifugen, Tuttlingen, Germany) to verify the completeness
of the cell lysis. After the first centrifugation step, 25% (w/v)
trichloroacetic acid was added to each sample to cause protein
precipitation, followed by 15 s of vortexing, sonication for
1 min and another vortex step for 15 s. Centrifugation was per-
formed for a second time under the same conditions as
described above. The supernatants were filtered using
Sartorius Minisart syringe filters with a pore size of 0.45 µm
and then diluted in the ratio of 1 : 5 with 50 mM ammonium-
formate buffer (pH = 6.0) directly into HPLC vials. The vials
were placed into the pre-cooled autosampler (4 °C) of the
HPLC system for RP-ICP-MS analysis. In order to determine
the extraction efficiency, the supernatants obtained after the
second centrifugation step were filtered, weighted and diluted
with 3% nitric acid. The platinum concentration of the
samples was determined by ICP-MS, using the same measure-
ment conditions as described above and the instrumental
parameters as summarized in Table S1.†
Monitoring the biotransformation of platinum(IV) complexes
by RP-ICP-MS
RP-ICP-MS measurements were performed on an Agilent 1260
Infinity Bio-inert HPLC system (Agilent Technologies,
Waldbronn, Germany) hyphenated to an Agilent 8800 ICP-MS/
MS instrument (Agilent Technologies, Tokyo, Japan).
Chromatographic separations were performed using an
Atlantis T3 C18 analytical column (150 mm L × 2.1 mm i.d.,
3 µm dp, 100 Å pore size) equipped with an Atlantis T3 guard
column (20 mm L × 2.1 mm i.d., 3 µm dp) from Waters
(Milford, USA). Chromatographic conditions are summarized
in Table S2.† The ICP-MS/MS was equipped with a torch with
1.5 mm inner diameter, platinum cones and the brass-based
lens system in order to withstand the high organic solvent
load. Oxygen was introduced as the option gas and admixed
with the aerosol before entering the ICP-MS to avoid carbon
deposition on the cones. Data processing was performed with
the Agilent MassHunter software package (Workstation
Software, Version C.01.03, 2016). The ICP-MS operation para-
meters and chromatographic conditions used are summarized
in Tables S1 and S2,† respectively. Samples were measured in
triplicates and an aqueous solution of complex 3 (50 µM) was
measured after every third sample as quality control.
Results and discussion
Determination of the platinum concentration in blood
compartments by ICP-MS
The platinum concentration of the compounds under investi-
gation was determined by ICP-MS in whole blood, blood
pellets and plasma after centrifugation and microwave-assisted
acid digestion at different time points over 24 hours (Fig. 2).
Complexes 1–3 showed a similar platinum distribution pattern
in blood compartments. Initially, the three platinum(IV) com-
pounds were predominantly localized in the plasma (∼80–90%
of platinum). After 24 h, 20–30% of platinum was found in the
blood cells, indicating a slow penetration of the compounds
and/or their metabolites from the plasma into the blood cells.
Paper Dalton Transactions
5254 | Dalton Trans., 2018, 47, 5252–5258 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/1
/2
01
8 
1:
19
:3
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
However, there was no significant change observed in the plati-
num distribution of the compounds after 2 h, compared to
time point 0. These results could be explained by the hydro-
philic character expressed as negative log Po/w values of the
complexes (summarized in Table 1), which might prevent
them from passing through biological membranes efficiently.
Complex 4, in contrast, accumulates 30% of platinum already
at time point 0 in the red blood cells. It also penetrates the
blood cells in a significantly faster way than the other three
platinum(IV) complexes investigated, with around 60% of plati-
num found in blood cells after 2 h. One possible explanation
of these phenomena might be the higher lipophilicity of
complex 4 (log Po/w = 0.78, Table 1) compared to the other
investigated platinum(IV) compounds. Complex 4 also dis-
played rapid saturation kinetics of accumulation: the distri-
bution of drug-related platinum after 2 hours is close to that
observed after 24 hours of incubation. Assuming exponential
kinetics, the rate constant of the accumulation of complex 4 in
blood cells was calculated from the proportion of the drug-
related platinum in the cells as a function of time. According
to the kinetic model, 59.7 ± 0.9% of the drug-related platinum
can be found inside the blood cells in equilibrium, with a
first-order rate constant of 1.2 ± 0.1 h−1. These results are in
good agreement with a previous in vivo study addressing the
anticancer efficacy of complex 4 in a murine CT-26 colon
cancer model and its platinum distribution in different mice
organs, tumors, blood pellets and serum.29 In this case, 24 h
after the last oral administration (either after single or mul-
tiple administrations of compound 4) around 60% of platinum
was found in the blood pellet of the mice.29 Recent in vitro
studies also revealed high platinum accumulation in SW480
(colon carcinoma) cells after 2 h exposure to complex 4.9
Evaluation of extraction procedures for platinum(IV)
compounds from whole human blood
Investigating the kinetic inertness of platinum(IV) complexes
in whole human blood requires a rapid and robust sample
preparation. For this purpose, two different sample prepa-
ration protocols have been evaluated to extract platinum(IV)
complexes directly from whole human blood with respect to
their extraction efficiency and time consumption. Method A
was based on ice-cold acetonitrile for extraction and the extrac-
tion efficiency values are summarized in Table 1. For com-
plexes 2 and 3, extraction efficiencies of approx. 60% were
obtained, whereas compound 4 was extracted to an extent of
∼75%. However, the procedure turned out to be unsuitable for
the most hydrophilic compound 1, showing a poor recovery
between 10 and 15% which could be also due to the poor solu-
bility of complex 1 in acetonitrile. For this reason, a second
extraction method was developed and evaluated using freeze-
thawing for cell disruption and trichloroacetic acid for protein
precipitation, avoiding the usage of organic solvents (Method
B, extraction efficiency values are summarized in Table 1). This
method yielded higher extraction efficiencies for all platinum(IV)
Fig. 2 Distribution of drug-related platinum in plasma and blood cells upon incubation of four different platinum(IV) compounds in whole blood. A:
complex 1, B: complex 2, C: complex 3, and D: complex 4. Blood samples were spiked with pharmacologically relevant concentrations of the plati-
num(IV) compounds (10 µM) and platinum concentrations were determined in different blood fractions by ICP-MS after centrifugation and micro-
wave digestion. Error bars correspond to the standard deviation of three methodological replicates.
Table 1 Extraction efficiency of the platinum(IV) complexes from whole
human blood using extraction method A with acetonitrile and extraction
method B with freeze-thawing. The values are given as the average
value and standard deviation from three independent methodological
replicates. The lipophilicity of the compounds is expressed as the
octanol-water partition coefficient (log Po/w), calculated by employing a
model specially developed for the prediction of log P values of platinum
(II) and platinum(IV) complexes30
Compound
Recovery (%),
Method A
Recovery (%),
Method B log Po/w
Complex 1 11.7 ± 1.1 75.7 ± 2.3 −2.1
Complex 2 60.4 ± 1.3 75.9 ± 1.2 −1.4
Complex 3 60.5 ± 2.3 79.8 ± 1.2 −1.5
Complex 4 73.4 ± 4.3 40.3 ± 0.8 0.78
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complexes (between 70 and 80%) compared to method A,
except for the most lipophilic compound 4, which was only
extracted to an extent of around 40%. The advantages of
method A are its simplicity and low time requirement (less
than 4 minutes). Furthermore, this method is directly compati-
ble with hydrophilic interaction liquid chromatography as
acetonitrile serves as the weak eluent in the case of this chro-
matographic mode. As a consequence, time-consuming evap-
oration and solvent reconstitution can be avoided. Extraction
method B includes more extraction steps and is more time-
consuming (approx. 9 minutes) than method A. The extraction
efficiency is comparable or higher than for method A except
for compound 4. The purely aqueous extracts obtained with
this method can be directly injected into a reversed-phase
column. Based on these results, the cold organic extraction
method (method A) was used for complex 4 and the acidic
extraction method (method B) for the other three platinum(IV)
compounds to directly extract the complexes and their metab-
olites from whole human blood.
Studying the biotransformation of platinum(IV) complexes in
whole human blood using RP-ICP-MS
The platinum(IV) compounds were incubated in whole human
blood over 24 h and the developed extraction methods were
used to monitor their kinetics of biotransformation in whole
human blood by RP-ICP-MS. Overlaid chromatograms of plati-
num(IV) compounds are shown in Fig. 3. The results indicate
that complex 1 and 3 remain stable over 24 hours in blood, as
no metabolites or decrease of the signal corresponding to the
parent compound was observed in the chromatograms. In the
case of complex 2, only the intact complex was observed over a
time period of 6 hours. After one day, the parent compound
and also a significant amount of oxaliplatin could be detected,
most likely due to the reductive biotransformation in the
blood. However, as every xenobiotic agent in the bloodstream
would travel through the liver (and other organs with meta-
bolic capacity) multiple times during the 6 hour-period,
complex 2 can also be regarded stable in blood on a pharmaco-
logically relevant timescale. Compound 4, in contrast, showed
rapid metabolisation and a decrease of the signal corres-
ponding to the parent compound in the blood; the intact
prodrug could not be detected any more after 24 hours of incu-
bation. The half-life of complex 4 in blood was calculated to be
45.4 ± 3.3 min, which was determined by fitting a first-order
kinetic model to the data illustrated in Fig. 3. There seems to
be a correlation observable between the extent of penetration
into blood cells (Fig. 2) and the kinetics of biotransformation
of the platinum(IV) compounds. Complexes 1–3 remain mostly
in the plasma, resulting also in a comparable stability towards
biotransformation on a pharmacologically relevant time scale.
Compound 4, in contrast, accumulates platinum to a higher
extent in blood cells (30% at 0 h and 60% at 2 h) resulting in a
short half-life in blood, which clearly demonstrates the impor-
tant role of blood cells in the metabolism of platinum(IV) com-
plexes. Furthermore, no notable amounts of hydrophilic plati-
num(II)-metabolites were detected for 4 after 24 h in blood,
while in the case of 2, a significant amount of free, unbound,
extractable oxaliplatin could be observed after the same incu-
Fig. 3 RP-ICP-MS chromatograms of the platinum(IV) compounds after incubation (10 µM) in whole human blood for 0 h, 0.5 h, 1 h, 2 h, 6 h and
24 h at 37 °C. (A) Complex 1, (B) complex 2, (C) complex 3 and (D) complex 4. Samples were measured in triplicates and an aqueous solution of
complex 3 was injected after every third sample as quality control and used for normalisation.
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bation period. One reason behind these phenomena might be
the more reactive platinum(II)-core of complex 4.9,28
Compound 4 is featuring fast-leaving equatorial chlorido
ligands, which are capable of binding covalently to proteins
with much faster kinetics compared to the oxaliplatin- or car-
boplatin-core. However, other reasons might also be the
higher lipophilicity and the faster reduction of compound 4
compared to complexes 1–3. The biotransformation of
complex 4 is in accordance with the results obtained for satra-
platin during evaluation in clinical trials, which showed rapid
metabolisation once in the bloodstream with several metab-
olites found in plasma ultrafiltrate of patients.13 Incubation of
satraplatin in whole human blood in vitro resulted in a half-
life for the disappearance of the parent compound of only
6.3 min which the authors attributed to the presence of red
blood cells.14 Despite the observed rapid metabolism of satra-
platin in the bloodstream, it advanced to clinical phase III
trials,12,31 which suggests that platinum(IV) complexes are
sufficiently stable to be used as oral drugs. Also in the case of
complex 4, despite the extensive biotransformation observed
in this study, it showed anticancer activity in a murine colon
cancer model CT-26 after i.p. and p.o. administration as well
as efficacy in the leukemia L1210 mouse model.29
Conclusions
The fate of platinum(IV) compounds comprising different
coordination spheres was investigated in whole human blood
by studying (1) the fractionation of the drugs between blood
cells and plasma next to (2) the chemical inertness of the
intact and free platinum(IV) compounds upon ex vivo incu-
bation. The latter task could be fulfilled after developing fit for
purpose extraction protocols followed by RP-ICP-MS analysis.
The study showed that the extent of biotransformation was
dependent on the platinum accumulation in blood cells, indi-
cating that the environment plays an important role in the
reduction of platinum(IV) agents. Moreover, the coordination
sphere also seems to have an impact on the reduction of plati-
num(IV) complexes in blood, as the most significant biotrans-
formation was observed for the platinum(IV) complex bearing
equatorial chlorido ligands.
However, careful balancing between inertness and reactivity
and between selectivity and cytotoxicity cannot be emphasized
enough: if platinum(IV) agents reach their targets successfully,
but are not reduced and do not release cytotoxic platinum(II)
agents, their anticancer activity in vivo would be unsatisfactory.
Therefore, further studies are needed to find the optimal
coordination spheres with the desired rate of reduction,
besides investigating the effect of the liver and other organs on
the biotransformation of platinum(IV) agents.
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